Does Rallies show Form 4 insider transactions for KURA?

Yes. Rallies tracks KURA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KURA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KURA. It does not provide personalized investment advice.

KURA (Kura Oncology, Inc.) Stock Analysis - Insider Trades

Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of May 21, 2026, KURA trades at $10.27 with a market cap of $816.72M and a P/E ratio of -3.19. KURA moved +15.29% today. Year to date, KURA is +8.39%; over the trailing twelve months it is +62.07%. Its 52-week range spans $5.41 to $19.94. Analyst consensus is strong buy with an average price target of $28.13. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KURA stock inside the company?

Recent KURA insider activity includes Powl Brian T. sold 4.84K, Powl Brian T. sold 1.57K, FORD KATHLEEN sold 1.81K, Leoni Mollie sold 3.65K, and Leoni Mollie sold 2.23K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KURA Key Metrics

Key financial metrics for KURA
Metric	Value
Price	$10.27
Market Cap	$816.72M
P/E Ratio	-3.19
EPS	$-3.18
Dividend Yield	0.00%
52-Week High	$19.94
52-Week Low	$5.41
Volume	11.20K
Avg Volume	0
Revenue (TTM)	$67.48M
Net Income	$-278.67M
Gross Margin	0.00%

Recent KURA Insider Trades

Powl Brian T. sold 4.84K (~$40.97K) on Jan 27, 2026.
Powl Brian T. sold 1.57K (~$13.30K) on Jan 27, 2026.
FORD KATHLEEN sold 1.81K (~$15.34K) on Jan 27, 2026.
Leoni Mollie sold 3.65K (~$30.92K) on Jan 27, 2026.
Leoni Mollie sold 2.23K (~$18.89K) on Jan 27, 2026.

Latest KURA News

Kura Oncology Reports Q1 KOMZIFTI Launch Drives Revenue Growth, Extends Cash Runway — May 13, 2026
Kura Oncology’s Darlifarnib-Cabozantinib Combo Yields 44% ORR and 94% DCR in RCC — Apr 17, 2026
Kura to Present Phase 1 ccRCC Data on Darlifarnib Plus Cabozantinib at IKCS Europe — Apr 9, 2026
Komzifti Nets $2.1M Launch Revenue, Unlocks $135M Milestone for Kura Oncology — Mar 6, 2026
Kura Oncology Nets $135M KOMZIFTI Milestone, Q4 Loss Narrows to $8M — Mar 5, 2026

KURA Analyst Consensus

10 analysts cover KURA: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.13.

Common questions about KURA

Who is trading KURA stock inside the company?: Recent KURA insider activity includes Powl Brian T. sold 4.84K, Powl Brian T. sold 1.57K, FORD KATHLEEN sold 1.81K, Leoni Mollie sold 3.65K, and Leoni Mollie sold 2.23K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KURA?: Yes. Rallies tracks KURA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KURA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KURA. It does not provide personalized investment advice.